NIRVF (Nirvana Life Sciences) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 04, 2026)


What is Nirvana Life Sciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nirvana Life Sciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NIRVF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Nirvana Life Sciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nirvana Life Sciences Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's Margin of Safety % (DCF Earnings Based) falls into.


Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.